IP Library Granted Patent US 7,608,701
Granted Patent B2
US 7,608,701 · App. 11/701,576 · Granted Oct 27, 2009

Corticotropin releasing factor 2 receptor agonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,608,701
App. No.
11/701,576
Granted
Oct 27, 2009
Kind
B2
Abstract

Isolated corticotropin releasing factor derivatives, and nucleic acids encoding the same, are effective for treating corticotropin releasing factor 2 receptor modulated disorders such as muscular dystrophy.

Claims (46)

1. An isolated nucleic acid encoding a non-native peptide, wherein the non-native peptide comprises the sequence

ZGPPISIDLPX 11 X 12 LLRKX 17 IEIEKQEKEKQQAX 31 X 32 NAX 35 X 36 LX 38 X 39 X 40 (SEQ ID NO: 531);

wherein:

X 11 is selected from F, Y, L, I, and T;

X 12 is selected from Q, W, and Y;

X 17 is selected from V and M;

X 31 is selected from T and A;

X 32 is selected from N and T;

X 35 is selected from R and L;

X 36 is selected from L and I;

X 38 is selected from D and A;

X 39 is selected from T and R; and

X 40 is selected from I and V;

and variants thereof having at least 95% sequence identity to said peptide.

2. An isolated nucleic acid according to claim 1 , wherein the variant has at least 97% sequence identity to said non-native peptide.

3. An isolated nucleic acid encoding for a non-native peptide, wherein the non-native peptide comprises the sequence of SEQ ID NO: 278, and variants thereof having at least 95% sequence identity to said non-native peptide.

4. An isolated nucleic acid according to claim 3 , wherein the variant has at least 97% sequence identity to said non-native peptide.

5. An isolated nucleic acid according to claim 1 , wherein X 11 is selected from F, L, T, and Y.

6. An isolated nucleic acid according to claim 1 , wherein X 11 X 12 are selected from the group consisting of FQ, YQ, YW, LQ, LY, IY, and TY.

7. An isolated nucleic acid according to claim 6 , wherein X 31 X 32 are selected from the group consisting of AN, and TT.

8. An isolated nucleic acid according to claim 7 , wherein X 35 X 36 are selected from the group consisting of RL, LL, and RI.

9. An isolated nucleic acid according to claim 7 , wherein X 38 X 39 X 40 are selected from the group consisting of DTI, ARI, ATI, DRV, and ARV.

10. An isolated nucleic acid according to claim 6 , wherein X 35 X 36 are selected from the group consisting of RL, LL, and RI.

11. An isolated nucleic acid according to claim 6 , wherein X 38 X 39 X 40 are selected from the group consisting of DTI, ARI, ATI, DRV, and ARV.

12. An isolated nucleic acid according to claim 1 , wherein X 31 X 32 are selected from the group consisting of AN, and TT.

13. An isolated nucleic acid according to claim 12 , wherein X 35 X 36 are selected from the group consisting of RL, LL, and RI.

14. An isolated nucleic acid according to claim 13 wherein X 38 X 39 X 40 are selected from the group consisting of DTI, ARI, ATI, DRV, and ARV.

15. An isolated nucleic acid according to claim 12 , wherein X 38 X 39 X 40 are selected from the group consisting of DTI, ARI, ATI, DRV, and ARV.

16. An isolated nucleic acid according to claim 1 , wherein X 35 X 36 are selected from the group consisting of RL, LL, and RI.

17. An isolated nucleic acid according to claim 16 , wherein X 38 X 39 X 40 are selected from the group consisting of DTI, ARI, ATI, DRV, and ARV.

18. An isolated nucleic acid according to claim 1 , wherein X 38 X 39 X 40 are selected from the group consisting of DTI, ARI, ATI, DRV, and ARV.

19. An isolated nucleic acid according to claim 1 , wherein the non-native peptide comprises a sequence selected from the group consisting of SEQ ID NO: 22, 144, 148, 149, 151, 278, 279, 286, 288, 311, 349, 350, 351, 352, and 353.

20. An isolated nucleic acid encoding for a non-native peptide, wherein the non-native peptide comprises the sequence

ZGPPISIDLPX 11 X 12 LLRKX 17 IEIEKQEKEKQQAX 31 X 32 NAX 35 X 36 LX 38 X 39 X 40 (SEQ ID NO: 531);

wherein:

X 11 is selected from F, Y, L, I, and T;

X 12 is selected from Q, W, and Y;

X 17 is selected from V and M;

X 31 is selected from T and A;

X 32 is selected from N and T;

X 35 is selected from R and L;

X 36 is selected from L and I;

X 38 is selected from D and A;

X 39 is selected from T and R; and

X 40 is selected from I and V.

21. An isolated nucleic acid encoding for a non-native peptide, wherein the non-native peptide comprises the sequence of SEQ ID NO: 278.

Assignments (7)
CORRECTIVE ASSIGNMENT TO CORRECT THE US PATENT NO. 8,050,873 PREVIOUSLY RECORDED ON REEL 040183 FRAME 0129. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Feb 22, 2018
From: WARNER CHILCOTT COMPANY, LLC
To: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 045417/0593 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2016
From: WARNER CHILCOTT COMPANY, LLC
To: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
Reel/Frame 040183/0129 →
RELEASE OF SECURITY INTEREST Recorded Oct 31, 2013
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 031531/0538 →
SECURITY AGREEMENT Recorded Mar 30, 2011
From: WARNER CHILCOTT COMPANY LLC
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 026064/0607 →
RELEASE - REEL 023456, FRAME 0052 Recorded Mar 29, 2011
From: CREDIT SUISSSE AG, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
To: WARNER CHILCOTT COMPANY LLC
Reel/Frame 026042/0046 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2010
From: PROCTER & GAMBLE COMPANY, THE
To: WARNER CHILCOTT COMPANY, LLC
Reel/Frame 023796/0417 →
SECURITY AGREEMENT Recorded Nov 2, 2009
From: WARNER CHILCOTT COMPANY, LLC
To: CREDIT SUISSE, CAYMAN ISLANDS BRANCH, AS ADMINISTRATIVE AGENT
Reel/Frame 023456/0052 →